Evidence map›Paper›PMID 32500222›Full record

ReviewJournal of neural transmission (Vienna, Austria : 1996)2020

Development of neurodegeneration in amyotrophic lateral sclerosis: from up or down?

F Geser, L Fellner, J Haybaeck, G K Wenning

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of neural transmission (Vienna, Austria : 1996), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Imaging microtubule dynamics: A new frontier in biomarker development for neurodegenerative diseases.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Review
  3. Review
  4. Dysautonomia in Amyotrophic Lateral Sclerosis.International journal of molecular sciences · 2023
    Review
  5. Review
  6. Inactivation of the CBBrain pathology (Zurich, Switzerland) · 2021
    Article
  7. Emergent creativity in frontotemporal dementia.Journal of neural transmission (Vienna, Austria : 1996) · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

F GeserDepartment of Neurology, Hegau-Bodensee-Klinikum Singen, Virchowstr. 10, 78224, Singen (Hohentwiel), Germany. felix.geser@alumni.i-med.ac.at.ORCID 0000-0002-6796-7676
L FellnerDivision of Neurobiology, Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
J HaybaeckDepartment of Pathology, Neuropathology and Molecular Pathology, Medical University of Innsbruck, Innsbruck, Austria.
G K WenningDivision of Neurobiology, Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Amyotrophic lateral sclerosis (ALS) is a fatal neurological disease associated with neurodegeneration and intracellular pathological 43-kDa transactive response sequence DNA-binding protein (TDP-43) positive inclusions. The various clinical symptoms, such as motor disorders and cognitive impairment, reflect the degeneration of certain areas of the nervous system. Since the discovery of the significance of pathological TDP-43 for human disease including ALS, there has been an increasing number of studies reporting on the distribution and severity of neurodegeneration. These have rekindled the old debate about whether the first or second motor neuron is the primary site of degeneration in ALS. To shed light on this question, the following is a review of the relevant neuropathological studies.

Indexed as

Amyotrophic Lateral SclerosisDNA-Binding ProteinsHumansInclusion BodiesDNA-Binding ProteinsTARDBP protein, humanAmyotrophic lateral sclerosisLower motor neuronNeurodegenerationPathological 43-kDa transactive response sequence DNA-binding protein (TDP-43)Upper motor neuron

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.